|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 综合性卒中中心医疗质量的度量标准:对脑卒中联盟综合性卒中中心推荐意见的详细随访美国心脏协会/美国卒中协会对医疗专业人员的声明显示文摘背景卒中是一种主要的残疾和死亡原因。脑卒巾联盟提议,建立初级卒中中心(primary stroke center,PSC)和综合性卒中中心(comprehensive stroke center,csc)以分别为需要基本或高级下预的卒中患者提供适当的医疗服务。从2003年开始,美国医疗卫生机构认证联合委员会和各州已指定了一些PSC,目前正在考虑CSC的指定工作。为了推进该过程,我们提出了一套CSC应追踪监测医疗质量并促进质量改进的标准和相关数据。方法和结果我们分析了现有指南、综述和其他文献,以识别区分CSC与PSC的主要特征;起草了一套标准和相关数据元素,以评价这些卒中医疗方面的关键部分;然后通过反复修改达成共识。我们提出的这套标准和相关数据元素,涵盖了CSC内缺血性脯血管病、非外伤性蛛网膜下腔出血和腩出血患者专、№医疗的主要方面。结论我们提出这套标准,旨在为CSC的标准化数据采集提供一个框架,以促进当地医疗质量改进,并允许对来自不同CSC的数据进行合并分析。这将有助于将来CSC国家执行标准的制定。 | 何晟(译) 蔡可夫(译) 张元媛(译) 胡旻婧(译) 倪耀辉(译) 芮瑛(译) 柯开富(译) Dana Leifer Dawn M. Bravata J.J. (Buddy) Connors Ⅲ Judith A. Hinchey Edward C. Jauch S. Claibome Johnston Richard Latchaw William kikosky Christopher Ogilvy Adrian I. Qureshi Debbie Summers Gene Y. Sung Linda S. Williams Richard Zorowitz | 2011 | 国际脑血管病杂志2011，19，3： | 21 |
| 2 | 2018年急性缺血性卒中患者早期管理指南美国心脏协会/美国卒中协会为医疗专业人员制定的指南显示文摘背景和目的本指南旨在在单个文件中为治疗成年急性动脉性缺血性卒中患者的临床医生提供最新全面的系列推荐意见。目标读者为院前急救人员、医生、综合医疗保健人员和医院管理人员。本指南将取代2013年版指南及其后续更新。方法写作组成员由美国心脏协会卒中委员会的科学声明监督委员任命,代表各领域的医学专家。严格遵循美国心脏协会的利益冲突原则。不允许写作组成员对存在企业利益关系的相关议题进行讨论或投票。所有推荐意见必须得到写作组成员的一致通过,除非企业利益关系妨碍了成员投票。由4名同行评议专家以及卒中委员会的科学声明监督委员会和领导委员会成员对指南草案进行发布前评审。本指南采用了美国心脏病学学会/美国心脏协会2015年推荐意见分类和证据级别标准以及新版美国心脏协会指南格式。结果本指南详细介绍了院前医疗、紧急和急诊评估、静脉和血管内治疗以及院内管理,包括在发病后最初2周内启用的二级预防措施。本指南支持院前和院内卒中医疗系统的一体化概念。结论本指南基于目前可获得的最佳证据。然而,许多情况资料有限,迫切需要对急性缺血性卒中的治疗进行持续研究。 | William J. Powers Alejandro A. Rabinstein Teri Ackerson Opeolu M. Adeoye Nicholas C. Bambakidis Kyra Becker José Biller Michael Brown Bart M. Demaerschalk Brian Hoh Edward C. Jauch Chelsea S. Kidwell Thabele M. Leslie-Mazwi Bruce Ovbiagele Phillip A. Scott Kevin N. Sheth Andrew M. Southerland Deborah V. Summers David L. Tirschwell 徐加平 刘慧慧 张霞 石际俊 黄志超 尤寿江 郭志良 肖国栋 杜万良 曹勇军 | 2018 | 国际脑血管病杂志2018，26，2： | 19 |
| 3 | 2019年急性缺血性卒中患者早期管理指南:针对2018年急性缺血性卒中早期管理指南的更新美国心脏协会/美国卒中协会为医疗专业人员制定的指南显示文摘背景和目的本指南旨在在单个文件中为治疗急性动脉性缺血性卒中患者的临床医生提供最新的全面系列推荐意见。目标读者为院前急救人员、医生、综合医疗保健人员以及医院管理人员。本指南将取代2013年版急性缺血性卒中(acute ischemic stroke,AIS)指南,同时也是对2018年版AIS指南的更新。方法写作组成员由美国心脏协会(American Heart Association,AHA)卒中委员会的科学声明监督委员会任命,代表各领域的医学专家。写作组成员不得对存在企业利益关系的相关议题进行讨论或投票。对2013年版AIS指南的更新最初于2018年1月发表,该版指南已经过AHA科学咨询与协调委员会以及AHA执行委员会批准。2018年4月,在删除部分推荐意见后,该指南的修订版在AHA网站上在线发表。要求写作组审查原始文件并在必要时进行修订。2018年6月,写作组提交了一份经过细微更改并纳入新近发表的重要随机对照试验(受试者数量>100名且具有AIS发病后至少90 d的临床转归)的文件。经过14位专家进行同行评议后,写作组根据同行评议专家的意见进行了适当修改。目前的最终文件已经过写作组全体成员(除非企业利益关系妨碍了成员投票)以及AHA管理机构批准。本指南采用了美国心脏病学学会/AHA 2015年推荐意见分类和证据级别标准以及新版AHA指南格式。结果本指南详细介绍了院前医疗、紧急和急诊评估、静脉和血管内治疗以及院内管理,包括在发病后最初2周内启用的二级预防措施。本指南支持院前和院内卒中医疗系统的一体化概念。结论本指南基于现有证据提供了总体推荐意见,用于指导治疗成年急性动脉性缺血性卒中患者的临床医生。然而,许多情况资料有限,迫切需要对AIS的治疗进行持续研究。 | William J.Powers Alejandro A.Rabinstein Teri Ackerson Opeolu M.Adeoye Nicholas C.Bambakidis Kyra Becker Jose Biller Michael Brown Bart M.Demaerschalk Brian Hoh Edward C.Jauch Chelsea S.Kidwell Thabele M.Leslie-Mazwi Bruce Ovbiagele Phillip A.Scott Kevin N.Sheth Andrew M.Southerl Deborah V.Summers Tirschwell 徐加平(译) 庄圣(译) 郭志良(译) 黄志超(译) 尤寿江(译) 刘慧慧(译) 张霞(译) 石际俊(译) 肖国栋(译) 曹勇军(译) 刘春风(译) | 2020 | 国际脑血管病杂志2020，28，1： | 18 |
| 4 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study显示文摘 | Patrick Marcellin Edward Gane Maria Buti Nezam Afdhal William Sievert Ira M Jacobson Mary Kay Washington George Germanidis John F Flaherty Raul Aguilar Schall Jeffrey D Bornstein Kathryn M Kitrinos G Mani Subramanian John G McHutchison E Jenny Heathcote | 2012 | The Lancet2012，，： | 14 |
| 5 | Epithelial ovarian cancer:An overview显示文摘Ovarian cancer is the second most common gyneco-logical cancer and the leading cause of death in the United States. In this article we review the diagnosis and current management of epithelial ovarian cancer which accounts for over 95 percent of the ovarian malignancies. We will present various theories about the potential origin of ovarian malignancies. We will discuss the genetic anomalies and syndromes that may cause ovarian cancers with emphasis on Breast cancer type 1/2 mutations. The pathology and pathogenesis of ovarian carcinoma will also be presented. Lastly, we provide a comprehensive overview of treatment strategies and staging of ovarian cancer, conclusions and future directions. | Arpita Desai Jingyao Xu Kartik Aysola Yunlong Qin Chika Okoli Ravipati Hariprasad Ugorji Chinemerem Candace Gates Avinash Reddy Omar Danner Geary Franklin Anachebe Ngozi Guilherme Cantuaria Karan Singh William Grizzle Charles Landen Edward E Partridge Valerie Montgomery Rice E Shyam P Reddy Veena N Rao | 2014 | World Journal of Translational Medicine2014，3，1： | 10 |
| 6 | 国际糖尿病足工作组:糖尿病足溃疡分类指南——《国际糖尿病足工作组:糖尿病足防治国际指南(2019)》的一部分显示文摘国际糖尿病足工作组(IWGDF)自1999年以来一直以循证为基础发布糖尿病足病的预防和管理指南。本文中针对日常临床工作中糖尿病足溃疡的分类提出了新指南,并对既有的分类进行了综述。新指南只对现患糖尿病足溃疡进行分类,不包括用于定义未来溃疡风险的分类系统。本指南的制定是基于对现有文献的综述以及专家对最大程度影响临床结局的8个关键因素的鉴定。分类级别是根据关键因素的数量、内部和外部有效性验证以及使用意向而制定的。判定分类评分的关键因素有3种:患者相关的因素(终末期肾衰竭)、肢体相关的因素(周围动脉病变和保护性感觉丧失)和溃疡相关的因素(面积、深度、部位、单发或多发以及感染)。特殊分类系统要考虑以下5种临床情况:①卫生专业人员之间交流;②预测单个溃疡预后;③对个案临床决策的辅助;④伤口评估,有感染或无感染及周围动脉病变(评估灌注及血管重建的潜在益处);⑤用于地方、区域或国家人群结局的稽查。指南推荐:①医务人员之间交流使用SINBAD系统。②无适用于预测个体溃疡预后的分类。③感染的评估采用美国传染病学会/国际糖尿病足工作组(IDSA/IWGDF)分类系统。④评估灌注及血管重建的潜在获益使用创面、缺血、足感染(WIfI)系统。⑤人群结局的稽查使用SINBAD系统。 | Matilde Monteiro-Soares David Russell Edward J Boyko William Jeffcoate Joseph L Mills Stephan Morbach Fran Game 无 王爱红(译) 冉兴无(审校) | 2019 | 感染.炎症.修复2019，20，4： | 10 |
| 7 | Abnormal subchondral bone remodeling and its association with articular cartilage degradation in knees of type 2 diabetes patients显示文摘Type 2 diabetes(T2 D) is associated with systemic abnormal bone remodeling and bone loss. Meanwhile,abnormal subchondral bone remodeling induces cartilage degradation, resulting in osteoarthritis(OA).Accordingly, we investigated alterations in subchondral bone remodeling, microstructure and strength in knees from T2 D patients and their association with cartilage degradation. Tibial plateaus were collected from knee OA patients undergoing total knee arthroplasty and divided into non-diabetic(n = 70) and diabetes(n = 51) groups. Tibial plateaus were also collected from cadaver donors(n = 20) and used as controls.Subchondral bone microstructure was assessed using micro-computed tomography. Bone strength was evaluated by micro-finite-element analysis. Cartilage degradation was estimated using histology. The expression of tartrate-resistant acidic phosphatase(TRAP), osterix, and osteocalcin were calculated using immunohistochemistry. Osteoarthritis Research Society International(OARSI) scores of lateral tibial plateau did not differ between non-diabetic and diabetes groups, while higher OARSI scores on medial side were detected in diabetes group. Lower bone volume fraction and trabecular number and higher structure model index were found on both sides in diabetes group. These microstructural alterations translated into lower elastic modulus in diabetes group. Moreover, diabetes group had a larger number of TRAP^+ osteoclasts and lower number of Osterix^+ osteoprogenitors and Osteocalcin^+ osteoblasts. T2 D knees are characterized by abnormal subchondral bone remodeling and microstructural and mechanical impairments, which were associated with exacerbated cartilage degradation. In regions with intact cartilage the underlying bone still had abnormal remodeling in diabetes group, suggesting that abnormal bone remodeling may contribute to the early pathogenesis of T2 D-associated knee OA. | Yan Chen Yong-Can Huang Chun Hoi Yan Kwong Yuen Chiu Qingjun Wei Jingmin Zhao X Edward Guo Frankie Leung William W Lu | 2017 | Bone Research2017，5，4： | 10 |
| 8 | Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt显示文摘AIM: To evaluate and validate the national trends and predictors of in-patient mortality of transjugular intrahepatic portosystemic shunt(TIPS) in 15 years.METHODS: Using the National Inpatient Sample which is a part of Health Cost and Utilization Project, we identified a discharge-weighted national estimate of 83884 TIPS procedures performed in the United States from 1998 to 2012 using international classification of diseases-9 procedural code 39.1. The demographic, hospital and co-morbility data were analyzed using a multivariant analysis. Using multi-nominal logistic regression analysis, we determined predictive factors related to increases in-hospital mortality. Comorbidity measures are in accordance to the Comorbidity Software designed by the Agency for Healthcare Research and Quality.RESULTS: Overall, 12.3% of patients died during hospitalization with downward trend in-hospitalmortality with the mean length of stay of 10.8 ± 13.1 d. Notable, African American patients(OR = 1.809 vs Caucasian patients, P < 0.001), transferred patients(OR = 1.347 vs non-transferred, P < 0.001), emergency admissions(OR = 3.032 vs elective cases, P < 0.001), patients in the Northeast region(OR = 1.449 vs West, P < 0.001) had significantly higher odds of inhospital mortality. Number of diagnoses and number of procedures showed positive correlations with in-hospital death(OR = 1.249 per one increase in number of procedures). Patients diagnosed with acute respiratory failure(OR = 8.246), acute kidney failure(OR = 4.359), hepatic encephalopathy(OR = 2.217) and esophageal variceal bleeding(OR = 2.187) were at considerably higher odds of in-hospital death compared with ascites(OR = 0.136, P < 0.001). Comorbidity measures with the highest odds of in-hospital death were fluid and electrolyte disorders(OR = 2.823), coagulopathy(OR = 2.016), and lymphoma(OR = 1.842).CONCLUSION: The overall mortality of the TIPS procedure is steadily decreasing, though the length of stay has remained relatively constant. Specific patient ethnicity, location, transfer status, primary diagnosis and comorbidities correlate with increased odds of TIPS in-hospital death. | Edward Wolfgang Lee Andrew Kuei Sammy Saab Ronald W Busuttil Francisco Durazo Steven-Huy Han Mohamed M El-Kabany Justin P Mc Williams Stephen T Kee | 2016 | World Journal of Gastroenterology2016，22，25： | 7 |
| 9 | Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease显示文摘 | Murat Toruner Edward V. Loftus W. Scott Harmsen Alan R. Zinsmeister Robert Orenstein William J. Sandborn Jean–Frederic Colombel Laurence J. Egan | 2008 | Gastroenterology2008，，4： | 6 |
| 10 | Approach to medical therapy in perianal Crohn’s disease显示文摘Perianal Crohn’s disease remains a challenging condition to treat and can have a substantial negative impact on quality of life.It often requires combined surgical and medical interventions.Anti-tumor necrosis factor(anti-TNF)therapy,including infliximab and adalimumab,remain preferred medical therapies for perianal Crohn’s disease.Infliximab has been shown to be efficacious in improving fistula closure rates in randomized controlled trials.Clinicians can be faced with a number of questions relating to the optimal use of anti-TNF therapy in perianal Crohn’s disease.Specific issues include evaluation for the presence of perianal sepsis,the treatment target of therapy,the ideal time to commence treatment,whether additional medical therapy should be used in conjunction with anti-TNF therapy,and the duration of treatment.This article will discuss key studies which can assist clinicians in addressing these matters when they are considering or have already commenced anti-TNF therapy for the treatment of perianal Crohn’s disease.It will also discuss current evidence regarding the use of vedolizumab and ustekinumab in patients who are failing to achieve a response to anti-TNF therapy for perianal Crohn’s disease.Lastly,new therapies such as local injection of mesenchymal stem cell therapy will be discussed. | Abhinav Vasudevan David H Bruining Edward V Loftus Jr William Faubion Eric C Ehman Laura Raffals | 2021 | World Journal of Gastroenterology2021，27，25： | 4 |
| 11 | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure显示文摘 | Aram V. Chobanian George L. Bakris Henry R. Black William C. Cushman Lee A. Green Joseph L. Izzo Daniel W. Jones Barry J. Materson Suzanne Oparil Jackson T. Wright Edward J. Roccella | 2003 | Hypertension: Journal of The American Heart Association2003，，6： | 4 |
| 12 | A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer显示文摘 | Edward J. Kim Edgar Ben‐Josef Joseph M. Herman Tanios Bekaii‐Saab Laura A. Dawson Kent A. Griffith Isaac R. Francis Joel K. Greenson Diane M. Simeone Theodore S. Lawrence Daniel Laheru Christopher L. Wolfgang Terence Williams Mark Bloomston Malcolm J. Moo | 2013 | Cancer2013，，15： | 3 |
| 13 | Autoimmune disorders and extraintestinal manifestations in first‐degree familial and sporadic inflammatory bowel disease. A case–control study显示文摘 | ElenaRicart RemoPanaccione Edward V.Loftus William J.Tremaine W. ScottHarmsen Alan R.Zinsmeister William J.Sandborn | 2006 | Inflamm Bowel Dis2006，，3： | 3 |
| 14 | Risk of Intestinal Cancer in Inflammatory Bowel Disease: A Population-Based Study From Olmsted County, Minnesota显示文摘 | Tine Jess Edward V. Loftus Fernando S. Velayos W. Scott Harmsen Alan R. Zinsmeister Thomas C. Smyrk Cathy D. Schleck William J. Tremaine L. Joseph Melton Pia Munkholm William J. Sandborn | 2006 | Gastroenterology2006，，4： | 3 |
| 15 | 抗生素耐药性环境中产生和转移的人类健康风险评估(HHRA)显示文摘[背景]直到最近,人们才明确环境能影响抗生素耐药性风险对临床结果的影响,但迄今为止,很少有文献记录正式评估这些风险的方法。[目标]我们研究可能的方法,并试图确定人类健康风险评估(HHRA)的研究需求,这项评估注重环境在抗生素耐药性病原体所致的抗生素治疗失败中所起的作用。[方法]作者参加了2012年3月4—8日在加拿大魁北克省举行的研讨会,定义抗生素耐药性风险与人类健康环境评估的范围和目标。我们专注于环境中耐药性产生'热点区域'的关键要素,(与食品无关的)暴露评估以及剂量反应,以描述风险特征,从而改善抗生素耐药性管理的方案。[讨论]识别传统风险评估中有助于评估环境中抗生素耐药性的各个新方面。包括:a)解释附加的选择压力对环境耐药基因组的作用,即随着时间的推移,促使抗生素耐药性细菌(ARB)产生;b)在相关的环境组成部分的'热点区域'中识别和描述水平基因转移(HGT)率;c)针对不同健康结局和途径的ARB剂量修改传统的剂量反应方法。[结论]我们建议将抗生素耐药性产生造成的环境影响纳入所有涉及ARB的HHRA过程之中。由于可用的数据有限,一种多标准决策分析方法将有助于进行环境中抗生素耐药性的HHRA,并使风险管理者了解环境抗生素耐药性。 | Nicholas J.Ashbolt Alejandro Amézquita Thomas Backhaus Peter Borriello Kristian K.Brandt Peter Collignon Anja Coors Rita Finley William H.Gaze Thomas Heberer John R.Lawrence D.G.Joakim Larsson Scott A.McEwen James J.Ryan Jens Schnfeld Peter Silley Jason R.Snape Christel Van den Eede Edward Topp 王晓宇 张伊人 操仪 | 2014 | 环境与职业医学2014，31，2： | 3 |
| 16 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 17 | Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation显示文摘 | Michael Charlton Edward Gane Michael P. Manns Robert S. Brown Michael P. Curry Paul Y. Kwo Robert J. Fontana Richard Gilroy Lewis Teperman Andrew J. Muir John G. McHutchison William T. Symonds Diana Brainard Brian Kirby Hadas Dvory-Sobol Jill Denning Sara | 2014 | Gastroenterology2014，，： | 2 |
| 18 | Prosthetic above-knee femoropopliteal bypass grafting: Five-year results of a randomized trial显示文摘 | Richard M Green William M Abbott Teruo Matsumoto Jock R Wheeler Normand Miller Frank J Veith Sam Money H Edward Garrett | 2000 | Journal of Vascular Surgery2000，，： | 2 |
| 19 | An approach for greenway suitability analysis显示文摘 | William Miller Michael G. Collins Frederick R. Steiner Edward Cook | 1998 | Landscape and Urban Planning1998，，2： | 2 |
| 20 | Infliximab for Crohn’s Disease: The First 500 Patients Followed Up Through 2009显示文摘 | Jennifer L. Seminerio Edward V. Loftus Jean-Frédéric Colombel Prabin Thapa William J. Sandborn | 2013 | Digestive Diseases and Sciences2013，，3： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员